MARKET

CERC

CERC

Cerecor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.430
+0.180
+8.00%
Closed 18:46 09/25 EDT
OPEN
2.270
PREV CLOSE
2.250
HIGH
2.440
LOW
2.260
VOLUME
246.87K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
1.520
MARKET CAP
182.01M
P/E (TTM)
-3.0000
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cerecor to Present at Upcoming Investor Conferences
ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive
GlobeNewswire · 09/10 11:00
Cerecor restarts early-stage CERC-002 study in Crohn’s disease
Cerecor (CERC) has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19.
Seekingalpha · 08/26 11:16
Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn's Disease
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc.
Benzinga · 08/26 11:13
Cerecor Announces Peer-Reviewed Publication Highlighting 'the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS'
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare
Benzinga · 08/13 11:27
Cerecor EPS misses by $0.08, misses on revenue
Cerecor (NASDAQ:CERC): Q2 GAAP EPS of -$0.18 misses by $0.08. Revenue of $1.34M (-3.6% Y/Y) misses by $0.91M. Shares -1.95% PM. Press Release
seekingalpha · 08/06 17:52
Cerecor Reports Second Quarter 2020 Financial Results and Business Update
-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the prevention of COVID-19 induced ARDSROCKVILLE, Md. and CHESTE
GlobeNewswire · 08/06 11:00
Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Michael F. Cola, Pres
GlobeNewswire · 08/05 11:00
Cerecor shares are trading higher after the company announced it has received rare pediatric disease designation by the FDA for CERC-006 for the treatment of lymphatic malformations.
Benzinga · 08/04 13:50
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERC. Analyze the recent business situations of Cerecor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERC stock price target is 11.00 with a high estimate of 12.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 81
Institutional Holdings: 49.04M
% Owned: 65.48%
Shares Outstanding: 74.90M
TypeInstitutionsShares
Increased
21
4.81M
New
26
8.57M
Decreased
15
244.69K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Director
Sol Barer
Chief Executive Officer
Mike Cola
Chief Executive Officer/Director
Michael Cola
Chief Financial Officer/Chief Accounting Officer
Christopher Sullivan
Other
Jamie Harrell
Other
Garry Neil
Other
Jeff Wilkins
Director
Suzanne Bruhn
Director
Joseph Miller
Independent Director
Steven Boyd
Independent Director
Phil Gutry
Independent Director
Magnus Persson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CERC
Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cerecor Inc stock information, including NASDAQ:CERC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERC stock methods without spending real money on the virtual paper trading platform.